BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
- Investigator
- Thomas J George
- Ages
- 18 Years - N/A
- Sexes
- All
Clinical trials
-
Safety, PKs, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advance Solid Tumors -
ADC MATCH Screening and Treatment Trial This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan) works…
- Investigator
- Thomas J George
- Ages
- 18 Years - N/A
- Sexes
- All